Who Can Participate?
Children aged 6 months to < 12 years with a diagnosis of moderate-to-severe eczema may participate.
Inclusion Criteria
* 1% of your body surface area is roughly equal to the palm of your hand (no wrists or fingers).
What Are the Benefits?
How Long Will the Study Last?
Edmonton - Alberta DermaSurgery Centre
Calgary - Dermatology Research Institute
Burlington - Halton Pediatric Allergy
Niagara Falls - Allergy Research Canada Inc.
Saskatoon - Skinsense Medical Research
Winnipeg - Wiseman Dermatology Research Inc.
No Doctors Found
Similar Trials
No Similar Trials FoundThe following information is from ClinicalTrials.gov
Last Update Posted: June 23, 2024
NCT06311682
LEO Pharma
Brief Summary:
The purpose of this trial is to test whether treatment with tralokinumab (administered subcutaneous injections [SC]) in combination with topical corticosteroids (TCS) is safe and effective to treat moderate-to-severe atopic dermatitis (AD) in children and infants. This will be judged by a range of assessments that rate the severity and extent of atopic dermatitis and its symptoms, as well as general health status and quality of life. The trial will last for up to 4 years. There will be visits every 2 weeks for the first year and every 6 weeks thereafter. Some of the visits will be conducted by phone. The study involves two different age groups: children aged 2 to under 12 years and infants aged 6 months to under 2 years. This trial compares tralokinumab +TCS to placebo + TCS for children with moderate-to-severe AD and evaluates tralokinumab + TCS for infants with moderate-to-severe AD. Infants will not receive placebo. All subjects will go through a screening process, which is the first part of the trial and will last up to 4 weeks. During this period, it will be checked if the child or infant meets the criteria to participate in the trial. The children will be randomly assigned to receive tralokinumab + TCS or placebo + TCS for the initial 16 weeks, with the treatment being double-blinded. During the first 16 weeks, children will have a 2 out of 3 chance of getting tralokinumab and a 1 out of 3 chance of getting placebo. Thereafter, all subjects will receive tralokinumab + TCS. The infants will receive tralokinumab + TCS as open-label treatment for the entire treatment period, meaning that the participants will know they are receiving tralokinumab. After stopping treatment, all participants will enter a 4-week safety follow-up period.
Condition or Disease:
Atopic Dermatitis
Intervention/Treatment:
Drug: Tralokinumab + TCSPhase:
Phase 3
Ages Eligible for Study:
6 Months and 11 Years (Child)
Sexes Eligible for Study:
All
Inclusion Criteria:
Age 6 months to <12 years at screening.
Body weight ≥9 kg at screening.
Diagnosis of AD as defined by the Hanifin and Rajka (1980) criteria for AD.
History of AD for: ≥12 months for subjects aged ≥6 years at screening and ≥3 months for subjects aged 6 months to <6 years at screening.
Documented inadequate response to mid-strength TCS within 6 months before the screening visit.
AD involvement of ≥10% body surface area at screening and baseline according to component A of SCORAD.
An EASI score of ≥16 at screening and baseline.
An IGA score of ≥3 at screening and baseline.
A Child Worst Itch NRS average score of ≥4 (subjects aged ≥6 years at screening) or a Scratch ObsRO average score of ≥4 (subjects aged <6 years at screening) during the week prior to baseline.
Exclusion Criteria:
Treatment with the topical corticosteroids (TCS), topical calcineurin inhibitors (TCI), topical phosphodiesterase-4 inhibitors (PDE-4), and topical Janus kinase inhibitors (JAK) within 1 week prior to baseline.
Treatment with bleach baths within 1 week prior to baseline.
Treatment with the immunomodulatory medications systemic immunosuppressive/immunomodulating drugs (e.g. methotrexate, cyclosporine, azathioprine, mycophenolate mofetil, Janus kinase inhibitors) and systemic corticosteroids (excludes inhaled, ophthalmic, or intranasal delivery) within 4 weeks prior to baseline.
Use of tanning beds or phototherapy within 4 weeks prior to baseline.
Treatment with a live (attenuated) or non-live vaccine within 30 days prior to the baseline visit.
Active dermatologic conditions that may confound the diagnosis of AD or would interfere with assessment of treatment such as seborrheic dermatitis, active skin infection, scabies, cutaneous T cell lymphoma, or psoriasis.
Clinically significant active chronic or acute infection requiring treatment with systemic antibiotics, antivirals, antifungals or antiprotozoal within 2 weeks before the baseline visit.
History of past or current hepatitis B or C including a positive hepatitis B or C test at screening.
Terms and Conditions – ClinicalTrials.gov
Purpose of ClinicalTrials.gov Database. The U.S. National Institutes of Health, Department of Health and Human Services, through its National Library of Medicine, has developed ClinicalTrials.gov to provide patients, family members, and members of the public current information about clinical research studies.
Can’t find a trial? Not sure which trial to choose? Complete a general registration and we’ll contact you with suitable trials.
Last Revised July 2024
ResearchTrials.org is committed to respecting your Personal Information (defined below) and is aware of your concern for privacy when using ResearchTrials.org. Further to this commitment, we have adopted a company-wide Privacy Policy that guides how we collect, use, disclose, update and protect the information you provide to us and when we delete such information.
Probity complies with the Personal Information Protection and Electronic Documents Act (“PIPEDA”) and other applicable privacy and health information legislation. One of the underlying principles of this legislation is to obtain your consent in order to collect, use or disclose your Personal Information (defined below), and to ensure that you clearly understand the policies and practices regarding how this information is handled.
“Personal Information” is information about an identifiable individual. This includes any information that can be linked to an individual’s identity, such as name, address, email, telephone number, age, gender, occupation, survey information, site registrations or any other information that might reasonably be used to identify someone. It does not apply to the information of non-individuals, such as corporations and other business entities and, generally speaking, to business contact information of physicians (“Physicians”) or pharmaceutical companies/medical device manufacturers (“Sponsors”).
Probity attempts to collect and use information that is accurate, up-to-date, and as complete as possible. Probity collects Personal Information from you only when it is voluntarily provided. Registration is not required for use of ResearchTrials.org. Anyone can visit the site and read our content. We do not provide copyright to the materials on our website and expect that you comply with the laws in your jurisdiction with respect to further use of any material obtained from the website.
When visitors fill out the “contact us” section of ResearchTrials.org the following Personal Information is collected:
Name;
Phone number;
Email address.
Medical condition or area of interest; and
Your location (Country, City, State or Province, Zip Code or Postal Code);
By providing your Personal Information, you are consenting to our use of your Personal Information for the Purposes outlined below. Further, by using our website, you agree with the terms of this Privacy Policy.
You may withdraw this consent at any time or update your information. To withdraw your consent or to update your information, contact the Privacy Officer by mail at:
Probity Medical Research Inc.
Attention: Privacy Officer
139 Union Street East
Waterloo, Ontario, Canada N2J 1C4
Probity collects your Personal Information for the following purposes (the “Purposes”):
to identify you;
to contact you about clinical research studies;
to enable a clinical research site in your area to contact you;
to confirm if your registration on ResearchTrials.org resulted in enrollment in any clinical trial, as well as the specific clinical trial(s) you enrolled in;
to ensure that we are achieving our goal of aiding enrollment in clinical trials;
to protect us both against error and fraud; and
to comply with legal requirements.
For Patients, the information you submit on ResearchTrials.org will be used for the above purposes. Because the clinical research sites are located in different countries, your personal information may be transmitted to your nearest research site (or research site you selected).
That research site may be in a different country than the location of the ResearchTrials.org database.
For Sponsors and Physicians, the information you submit on ResearchTrials.org will be used to contact you.
Personal Information will not be sold or rented and will not be exchanged with unaffiliated entities, except to fulfill the Purposes set out above, unless you are first notified and expressly consent to such transfer. Probity will seek to ensure that any third parties it shares your information with also comply with the terms of this Privacy Policy.
Probity is aware of your concern for privacy when using ResearchTrials.org. Probity takes reasonable steps to protect your Personal Information as you transmit your information from your computer to our websites and to protect your information from loss, misuse and unauthorized access, disclosure, alteration or destruction. All information transmitted to our website is secured using industry standard physical, technical, and administrative safeguards to secure data against foreseeable risks such as unauthorized use, access, disclosure, destruction, and modification. You should keep in mind, however, that no Internet transmission is ever 100% secure or error-free. In particular, e-mail sent to or from our website may not be secure, and you should therefore take special care in deciding what information you send to us via email.
Your Personal Information is kept in strict confidence; Probity utilizes appropriate security safeguards to keep your information confidential and secure. Only authorized personnel have access to your Personal Information and we do not release your Personal Information to third parties other than those third parties that are necessary to satisfy the Purposes (as defined above) for which the Personal Information was collected, including third party service providers. While we cannot guarantee that errors, loss or unauthorized access to your Personal Information will not occur, our procedures and systems are designed to protect your Personal Information from such events. When your Personal Information is no longer required to fulfill the identified Purposes, the information will be destroyed, erased, or made anonymous.
When you are contacted by a third party to participate in a clinical research study, Probity is no longer involved or responsible for collecting or safeguarding any further Personal Information you may provide to that third party. As such, we recommend that you obtain information regarding their privacy policies before participating.
As we expect the need for participants in clinical research studies to be ongoing, the Personal Information you provide will be kept indefinitely. If at any time you wish to remove or update your information from our database, please contact our Privacy Officer by mail at:
Probity Medical Research Inc.
Attention: Privacy Officer
139 Union Street East
Waterloo, Ontario, Canada N2J 1C4
Patients, Physicians and Sponsors have a right of access to their own Personal Information in a record that is in the custody or under the control of Probity, subject to some exceptions set out in applicable legislation. For example, organizations are required under PIPEDA to refuse to provide access to information that would reveal Personal Information about another individual. Further, organizations are authorized under PIPEDA to refuse access to Personal Information if disclosure would reveal confidential business information. Access may also be refused if the information is privileged or the information was generated in the course of a formal dispute resolution process.
If access is refused, in whole or in part, Probity will provide the reasons for the refusal. In cases where exceptions to access apply, Probity may withhold that information but will provide you with the remainder of the record.
If at any time you wish to access your personal information held by us, please contact us by mail at:
Probity Medical Research Inc.
Attention: Privacy Officer
139 Union Street East
Waterloo, Ontario, Canada N2J 1C4
The ResearchTrials.org web server captures the Internet Protocol (IP) addresses of each connection to the website and the specific web pages visited during that connection. An IP address is a number assigned to your computer by your Internet Service Provider so you can access the Internet and is generally considered to be non-personally identifiable information because in most cases it changes each time you connect to the Internet. IP addresses may be used to diagnose problems with our server, report aggregate information, determine the fastest route for your computer to use in connecting to the website, and administer and improve the website. Although the IP address and related information collected is stored in the server log files, no individual is authorized to access those files for any purpose other than system maintenance. We may also use this information to help improve our websites and our services by better understanding our audience.
Probity may also collect non-personally identifiable information in aggregate form to track data such as the total number of visits to our websites, the number of visitors to each page of our websites, and the domain names of our visitors’ Internet service providers. We may use this information, which remains in aggregate form, to understand how our visitors use our websites so that we may make the websites better.
Probity may also use “cookies” to administer our website, which are text packets sent by a server to a user’s web browser and then sent back unchanged by the user’s browser each time it accesses that server. Cookies are used for authenticating, tracking, and maintaining specific information about users, such as website preferences. No personally identifiable information is exchanged via cookies.
Probity reserves the right to modify or amend this Privacy Policy without notice and at any time and for any reason. An up-to-date version of this Privacy Policy may be obtained on our website.
This Privacy Policy is governed by the laws of Canada. By submitting Personal Information to us, you understand that your Personal Information will be subject to the laws of Canada.
You have the right to know how we protect your privacy and what you should expect from us. If you have questions or a complaint you may contact our Privacy Officer by mail at:
Probity Medical Research Inc.
Attention: Privacy Officer
139 Union Street East
Waterloo, Ontario, Canada N2J 1C4
register now